Sino Biopharmaceutical Ltd (SBMFF)
OTHER OTC:SBMFF
Want to see SBMFF full AI Analyst Report?
SBMFF Stock Chart & Stats
$0.77
-$0.01(-3.00%)
At close: 4:00 PM EST
$0.77
-$0.01(-3.00%)
Day’s Range― - ―
52-Week Range$0.49 - $1.24
Previous CloseN/A
Volume3.69K
Average Volume (3M)511.00
Market Cap
$11.80B
Enterprise Value$88.97B
Total Cash (Recent Filing)$19.82B
Total Debt (Recent Filing)$11.96B
Price to Earnings (P/E)42.8
Beta0.46
Next Earnings
Aug 26, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend Yield1.4%
Share Statistics
EPS (TTM)0.20
Shares Outstanding18,745,367,000
10 Day Avg. Volume800
30 Day Avg. Volume511
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market Cap7.54
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit3.56
Enterprise Value/Ebitda14.55
Forecast
1Y Price Target
$1.08Price Target Upside39.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.03
Revenue Forecast (FY)$4.58B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationFree cash flow rebounded in 2025 with FCF/net income near 0.82, showing reliable cash conversion from reported earnings. Durable cash generation supports sustained R&D investment, working capital needs and debt service, improving long-term financial flexibility and resilience.
High Gross MarginsPersistently high gross margins reflect a portfolio weighted to proprietary and higher-value specialty medicines. This structural margin advantage provides room to fund SG&A and R&D, sustain operating profit, and maintain pricing flexibility versus lower-margin competitors over the medium term.
Re-accelerating Revenue GrowthTop-line acceleration in 2025 signals improving demand or successful product momentum across therapeutic franchises. Sustained revenue growth enhances scale, supports investment in pipeline expansion and commercial capabilities, and strengthens the base for margin recovery and cash generation.
Bears Say
Rising LeverageA meaningful year-over-year increase in debt-to-equity reduces financial flexibility and raises interest and refinancing exposure. If profitability does not recover, higher leverage could constrain capital allocation for R&D or M&A and elevate solvency risk over the medium term.
Volatile And Falling Net MarginsA sharp decline and historical volatility in net margins indicate earnings are sensitive to pricing, SG&A, or one-off items. Sustained lower margins weaken cash buffers and make it harder to fund growth or absorb pricing/reimbursement pressures in China over the next several quarters.
Cash Conversion SensitivityLow coverage of operating profit by cash flow suggests working capital swings or non-cash items materially affect liquidity. This sensitivity raises the risk that earnings softness or inventory/receivables shifts could quickly pressure cash and force greater reliance on external funding.
Sino Biopharmaceutical News
SBMFF FAQ
What was Sino Biopharmaceutical Ltd’s price range in the past 12 months?
Sino Biopharmaceutical Ltd lowest stock price was $0.49 and its highest was $1.24 in the past 12 months.
What is Sino Biopharmaceutical Ltd’s market cap?
Sino Biopharmaceutical Ltd’s market cap is $11.80B.
When is Sino Biopharmaceutical Ltd’s upcoming earnings report date?
Sino Biopharmaceutical Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 97 days.
How were Sino Biopharmaceutical Ltd’s earnings last quarter?
Sino Biopharmaceutical Ltd released its earnings results on Mar 26, 2026. The company reported $0.001 earnings per share for the quarter, missing the consensus estimate of $0.009 by -$0.007.
Is Sino Biopharmaceutical Ltd overvalued?
According to Wall Street analysts Sino Biopharmaceutical Ltd’s price is currently Undervalued.
Does Sino Biopharmaceutical Ltd pay dividends?
Sino Biopharmaceutical Ltd pays a Quarterly dividend of $0.006 which represents an annual dividend yield of 1.4%. See more information on Sino Biopharmaceutical Ltd dividends here
What is Sino Biopharmaceutical Ltd’s EPS estimate?
Sino Biopharmaceutical Ltd’s EPS estimate is 0.02.
How many shares outstanding does Sino Biopharmaceutical Ltd have?
Sino Biopharmaceutical Ltd has 18,745,367,000 shares outstanding.
What happened to Sino Biopharmaceutical Ltd’s price movement after its last earnings report?
Sino Biopharmaceutical Ltd reported an EPS of $0.001 in its last earnings report, missing expectations of $0.009. Following the earnings report the stock price went down -3.034%.
Which hedge fund is a major shareholder of Sino Biopharmaceutical Ltd?
Currently, no hedge funds are holding shares in SBMFF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sino Biopharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.08 (39.96% Upside)
$1.08 (39.96% Upside)
Insider Transactions
Bought Shares
Worth $8.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.71%
12-Months-Change
Fundamentals
Return on Equity
11.03%
Trailing 12-Months
Asset Growth
21.38%
Trailing 12-Months
Company Description
Sino Biopharmaceutical Ltd
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
SBMFF Stock 12 Month Forecast
Average Price Target
$1.08
▲(39.96% Upside)
Technical Analysis
Innovent Biologics
―
3SBio
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
15.74% Insiders
2.94% Mutual Funds
<0.01% Other Institutional Investors
75.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---